Orbsen Therapeutics Shortlisted For Prestigious Innovation Award

Brian Molloy, CEO Orbsen Therapeutics pictured far left and Dr. Stephen J. Elliman, Head of Research at Orbsen Therapeutics pictured far right with the team from Orbsen Therapeutics.
Feb 05 2014 Posted: 11:15 GMT

Irish company Orbsen Therapeutics, the spin out company from REMEDI at NUI Galway is shortlisted for the Irish Times InterTradeIreland Innovation Awards 2014

NUI Galway startup company, Orbsen Therapeutics, have been shortlisted as finalists in the prestigious all-island Irish Times InterTradeIreland Innovation Awards 2014. This competition open to all companies on the island of Ireland, recognises excellence in groundbreaking product or services innovation. The overall winner of the award will be announced in Dublin in April.

Orbsen Therapeutics, an Irish company and the spin out company from REMEDI (Regenerative Medicine Institute) at NUI Galway, is seeking to develop innovative therapies for a range of diseases using Orbsen’s proprietary adult stem cell. The company is working with partners from all over the world to develop and commercialise its stem cell technologies, and now employs 12 people in Galway.

Mr Brian Molloy, CEO Orbsen Therapeutics said, “We are delighted to be shortlisted for the Innovation Awards 2014. Innovation is at the heart of what we do in Orbsen and we benefit hugely from the close relationship we have with the Research Institute and with NUI Galway. Over the past two years we have attracted over €20 million in research funding into Orbsen and into our network of 22 international and domestic collaborators. NUI Galway has been and will continue to be our primary collaborator on these grants as we move closer to the clinic and the development of new and innovative therapies.”

Dr. Stephen J. Elliman, Head of Research at Orbsen added, “Our unique stem cell isolation technologies give Orbsen Therapeutics, and indeed Ireland, the opportunity to become a leading global player in the Stem Cell Therapeutics space. We already have a number of early phase clinical trials that will start enrolling over the coming two to three years, and these have all been funded under the EU FP7 programme.”

Dr Jacinta Thornton, Acting Director, Ignite Technology Transfer Office, NUI Galway said “I would like to congratulate Orbsen Therapeutics on being shortlisted for this award. Since their inception, they have worked very closely with NUI Galway, in particular with REMEDI the world-leading centre for regenerative medicine, collaborating in research projects and winning large grant awards together. With the opening of the Centre for Cell Manufacturing Ireland (CCMI), Ireland’s first centre for stem cell manufacturing at NUI Galway, we are confident of further collaborative success together as Orbsen seeks to bring their products to the clinic.”

For further information on Orbsen Therapeutics visit www.orbsentherapeutics.com




Marketing and Communications Office